Skip to content
AnalystLens

Merck Annual Report, Year Ended Dec 31, 2006

Filing Date
Filed February 28, 2007
Period End
December 31, 2006
Security
MRK
In the record · 2016–202610-K1210-Q338-K87

MRK filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 87 current reports (8-K) between 2016 and 2026.

  1. Impairment8-K · Feb ’17Feb ’17
  2. Restructuring8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Aug ’21Aug ’21
  4. Restructuring8-K · Jul ’25Jul ’25

Summary

Summary of the 10-K filed February 28, 2007. Cited figures are marked; the original filing is the authoritative source.

Schering-Plough Corporation's 10-K for fiscal 2006 reports net sales of $10.6 billiona, up 11 percent from $9.5 billion in 2005, with net income available to common shareholders of $1.1 billion ($1.057 billion), compared with $183 million in 2005.

Diluted EPS was $0.71b versus $0.12. Results were significantly supported by equity income from the Merck/Schering-Plough cholesterol joint venture, which rose to $1.459 billion from $873 million, reflecting growing global sales of VYTORIN and ZETIA. Prescription Pharmaceuticals segment profit increased to $1.394 billion from $733 million, and gross margin improved to 65.1 percent.

Cash flow from operating activities was $2.2 billionc. The company is in the Build the Base phase of its Action Agenda. Key risks highlighted include the dependence of profits on the cholesterol franchise (which faced new generic entrants in December 2006), declining PEG-INTRON and REBETOL sales in Japan, the Consent Decree with the FDA, and several material government investigations.

The company settled the Massachusetts Investigation for an aggregate $435 milliond in August 2006 and pleaded guilty through a subsidiary in January 2007, while AWP litigation, third-party payor actions and other matters remain pending. The filing states that the U.S. operations generated negative cash flow in 2006 and are expected to do so again in 2007.

For 2007, the company does not provide numeric guidance but expects VYTORIN and ZETIA sales to grow, expects R&D expenses (excluding upfront payments) to grow faster than adjusted net sales, and anticipates approximately $100 million in annualized manufacturing cost savings. Total cash, cash equivalents and short-term investments less total debt was approximately $3.3 billion at year-end 2006.

Key Highlights

  1. Net sales rose 11 percent to $10.6 billion in 2006, from $9.5 billion in 2005, led by REMICADE, NASONEX, PEG-INTRON and TEMODAR.
  2. Net income available to common shareholders was $1.057 billion, or $0.71 diluted EPS, versus $183 million, or $0.12, in 2005.
  3. Equity income from the cholesterol joint venture with Merck totaled $1.459 billion, up from $873 million, driven by VYTORIN and ZETIA; global cholesterol franchise sales reached $3.9 billion.
  4. Prescription Pharmaceuticals segment profit grew to $1.394 billion from $733 million; gross margin improved to 65.1 percent from 64.8 percent.
  5. Research and development spending rose 17 percent to $2.2 billion, about 21 percent of net sales.
  6. Massachusetts Investigation settled for an aggregate $435 million ($180 million criminal fine and $255 million civil); AWP litigation and other investigations remain ongoing.
  7. Operating cash flow was $2.2 billion, while U.S. operations generated negative cash flow in 2006 and are expected to do so in 2007.

Frequently Asked Questions

  1. How much of Schering-Plough's 2006 profit came from the cholesterol joint venture with Merck?

    Equity income from the cholesterol joint venture was $1.459 billion in 2006, compared with income before income taxes of $1.483 billion for the consolidated company. This equity income is reported separately from net sales, so the joint venture's sales of VYTORIN and ZETIA are not included in reported net sales of $10.6 billion.

  2. What risks could affect the cholesterol franchise?

    The filing notes that generic forms of two competing cholesterol products were introduced in December 2006, and the U.S. cholesterol market is adjusting to them. Management expects VYTORIN and ZETIA sales to grow in 2007 despite this. Changes to change-of-control provisions could also affect strategic alternatives, potentially allowing Merck to acquire VYTORIN and ZETIA. In February 2007, a generic company filed an ANDA for ZETIA and challenged its listed U.S. patents.

  3. What is the status of the FDA Consent Decree and regulatory matters?

    Since 2002, Schering-Plough has operated under an FDA Consent Decree covering certain New Jersey and Puerto Rico manufacturing sites. The company completed the required revalidation programs and all 212 Significant Steps of the cGMP Work Plan by the end of 2005, and has obtained third-party certification subject to FDA acceptance. The decree is not lifted until the court dissolves it, and there is no assurance of timing. The filing also describes ongoing EMEA pharmacovigilance concerns identified in UK and EU inspections.

  4. What does management expect for 2007?

    Schering-Plough does not provide numeric guidance. It expects VYTORIN and ZETIA sales to grow in 2007, expects the number of clinical trial patients to rise substantially, and expects R&D expenses, excluding upfront payments, to grow faster than adjusted net sales. It also expects annualized manufacturing cost savings of about $100 million in 2007, which should improve gross margin.

  5. What is the company's balance sheet and liquidity position?

    At December 31, 2006, total assets were $16.071 billion, long-term debt was $2.414 billion, and shareholders' equity was $7.908 billion. Cash and cash equivalents were $2.666 billion and short-term investments were $3.267 billion. Total cash, cash equivalents and short-term investments less total debt was approximately $3.3 billion. The company's senior unsecured credit ratings were Baa1 (Moody's), A- (S&P) and A- (Fitch).